Share this article
Share this article
BILTHOVEN, Netherlands, April 7, 2021 /PRNewswire/ Intravacc, a global leader in translational research and development of viral and bacterial vaccines, today announced that it has obtained positive preclinical results for its SARS-CoV-2 Outer Membrane Vesicle (OMV) based recombinant Spike protein (rSp) candidate nose spray vaccine.
For the preclinical study four groups of mice and four groups of hamsters received two intranasal immunizations on day one and day 21. One group of mice and hamsters received a vaccine based on OMV s mixed with rSp (CovOMV) and the other a vaccine based on OMV s coupled to rSp based on Intravacc s proprietary OMV click technology (CovOMVclick). Control animals received respectively only OMV s or only rSp. On day 35 the mice blood samples were tested for virus neutralizing antibodies. The hamsters were challenged with SARS-CoV-2 on day 42 after blood collection. Over a period of seven days after challenges, thei
Intravacc announces positive preclinical data for its SARS-CoV-2 nose spray vaccine
notimerica.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from notimerica.com Daily Mail and Mail on Sunday newspapers.
Intravacc announces positive preclinical data for its SARS-CoV-2 nose spray vaccine
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.